Gilead Reports Phase 3 subgroup analysis Data for Risankizumab in Lupus nephritis

Gilead today announced Phase 3 subgroup analysis results for Risankizumab in patients with Lupus nephritis. The study demonstrated that Risankizumab achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Lupus nephritis and support the continued development of Risankizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Risankizumab was consistent with previous observations, with no new safety signals identified.